Disc Medicine Surges 38.31% on Trial Success as Silgan’s $3.4 Billion Deal and L3Harris’ $876 Million Contract Expand Operations

Mumbai, 19 October 2026: The US stock market witnessed a range of company-specific developments on 19 October 2026, spanning acquisitions, clinical trial updates, defence contracts, private placements and strategic partnerships. These announcements coincided with varied share-price movements across sectors, reflecting the diverse nature of corporate news released during the session. This report examines the key developments involving US-listed companies, outlining the announced transactions, financial details, operational implications and potential significance for their respective businesses.

Disc Medicine Shares Surge 38.31% as Phase 3 Trial Meets All Endpoints

Disc Medicine (NASDAQ: IRON) shares surged 38.31% to $78.62 during the 19 October 2026 trading session after the biotechnology company reported positive topline results from its Phase 3 APOLLO trial of bitopertin, an investigational treatment for erythropoietic protoporphyria (EPP), a rare inherited disorder that causes painful reactions to sunlight. The stock opened at $72.70, reached a high of $80.22 and a low of $69.98, against a previous close of $56.84.

The randomised, double-blind, placebo-controlled trial involved 183 adults and adolescents with EPP and met all primary and secondary endpoints, with statistically significant improvements compared with placebo. Patients receiving bitopertin recorded a 41.4% reduction in whole-blood metal-free protoporphyrin IX, a compound associated with the disorder’s symptoms. The trial also showed an increase of 12.2 hours in average monthly pain-free light exposure by the sixth month, alongside a significant reduction in phototoxic reactions.

Disc Medicine described bitopertin as generally well tolerated. Dizziness was the most common adverse event, affecting 50% of treated patients; reported cases were generally mild or moderate and temporary. No adverse events above Grade 3 were reported during the trial.

Following the results, the company plans to resubmit a New Drug Application to the US Food and Drug Administration by the end of 2026, with a potential regulatory decision anticipated by mid-2027. Bitopertin remains investigational, and approval is subject to the FDA’s review of its efficacy and safety data.

Cleveland-Cliffs Shares Gain 15.76% as 2027 EBITDA Forecast Exceeds $4 Billion

Cleveland-Cliffs Inc. (NYSE: CLF) shares rose 15.76% to $14.08 during the 19 October 2026 trading session after the steelmaker reported stronger third-quarter earnings and forecast adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) of more than $4 billion in 2027. The stock opened at $14.20, reached a high of $14.58 and a low of $12.94. The previous closing price was not provided in the supplied market data.

The company reported third-quarter adjusted EBITDA of $612 million for the three months ended 30 September, exceeding its guidance of $575 million and increasing by $326 million from the previous quarter. Net income reached $165 million, compared with a net loss of $134 million in the second quarter, while revenue rose to $5.6 billion from $5.2 billion. Adjusted earnings were $0.28 per share, beating the $0.21 estimate cited by FactSet.

Steel shipments increased to 4.2 million net tons from 4.0 million a year earlier, while the average selling price climbed to $1,177 per net ton from $1,032. Management expects fourth-quarter adjusted EBITDA of approximately $715 million, supported by higher steel prices despite seasonal pressures and maintenance costs.

The 2027 outlook reflects improved steel-price expectations and new customer contracts. Cleveland-Cliffs also reported $3.2 billion in liquidity at September-end and expects to reduce net debt to below 2.5 times EBITDA by mid-2027. However, the company plans to indefinitely idle Stelco’s galvanising lines amid oversupply in Canada’s galvanised steel market, while maintaining overall production volumes through a greater focus on hot-rolled products.

Silgan Holdings Shares Rise 6.61% After Announcing $3.4 Billion Trivium Acquisition

Silgan Holdings Inc. (NYSE: SLGN) shares rose 6.61% to $40.39 during the 19 October 2026 trading session after the company announced an agreement to acquire Trivium Packaging in an all-cash transaction valued at approximately $3.4 billion. The stock opened at $38.80, reached an intraday high of $40.46 and a low of $38.62. The previous closing price was not provided in the supplied market data.

The acquisition will combine Trivium with Silgan’s existing metal containers and food and beverage closure operations to establish Silgan MCC. Silgan expects to retain a 60% equity stake in the combined business, while funds affiliated with American Industrial Partners will hold the remaining 40% after contributing approximately $1 billion in cash. Silgan expects to receive around $2.3 billion in cash proceeds at closing and continue consolidating the business in its financial results.

Silgan MCC is projected to generate approximately $7.3 billion in annual sales and $1.2 billion in adjusted EBITDA, including anticipated synergies of $225 million over three years. The combined operation is expected to encompass more than 100 manufacturing facilities, with annual production capacity exceeding 27 billion cans and 30 billion closures. The transaction will also expand Silgan’s European presence and add exposure to aerosols and aluminium beverage bottles.

Management expects the transaction to increase adjusted earnings per share and free cash flow by at least 15%. The proposed structure also creates a potential path towards a tax-free spinoff of Silgan MCC, leaving Silgan focused on its dispensing and custom containers businesses. Completion remains subject to the applicable transaction conditions and approvals.

Also Read: What Is the New York Stock Exchange (NYSE)?

MicroVision Shares Rise 6.64% as Blue-Band Partnership Targets Intelligent Traffic Infrastructure

MicroVision, Inc. (NASDAQ: MVIS) shares gained 6.64% on Monday, 19 October 2026, following the announcement of a strategic alliance with Blue-Band LLC to develop lidar-based solutions for intelligent transportation systems (ITS). The collaboration brings together MicroVision’s short- and long-range lidar technologies and Blue-Band’s traffic management software to support transportation agencies seeking to improve road monitoring and modernise infrastructure.

At the latest reported market snapshot, MicroVision shares traded at $1.20, up $0.075, or 6.64%. The stock opened at $1.15 and recorded an intraday high of $1.21 and a low of $1.08. The announcement provides a potential commercial application for the company’s lidar portfolio, although the companies did not disclose a contract value, revenue forecast or deployment schedule.

The partnership will focus on three areas: monitoring vehicles, pedestrians and cyclists at intersections to support traffic signal operations; detecting roadway obstructions and hazardous conditions; and upgrading existing transportation infrastructure through integrated systems. These applications are intended to help agencies use sensor data to support traffic management and improve awareness of road conditions.

Blue-Band’s IntegraOS platform processes sensor data for traffic management systems and builds on its Integrator-AI technology. Its capabilities include visualisation, analytics and automated responses. MicroVision said the alliance would broaden its market reach and create opportunities to convert demand for intelligent transportation solutions into revenue-generating business.

MicroVision develops lidar-based perception technology for industrial, security, defence and automotive markets, while Blue-Band focuses on infrastructure systems and sensor-data processing. The announcement forms part of MicroVision’s commercial growth strategy, extending its potential applications beyond its established markets.

However, the financial contribution of the alliance remains unquantified. Investors and market observers will have to await further disclosures on customer adoption, deployments and commercial agreements to assess the partnership’s eventual business impact.

Fifth Third Bancorp Earnings Beat Estimates as NII Rises 49%, Shares Gain 1.06%

Fifth Third Bancorp (NYSE: FITB) reported third-quarter 2026 adjusted earnings per share of $1.13, exceeding the Zacks Consensus Estimate of $1.09 and rising from $0.93 in the year-ago quarter. Net income available to common shareholders under GAAP increased 36% year over year to $828 million. Results benefited from higher net interest income (NII), fee income, loan and deposit balances, and lower provisions for credit losses. However, revenue of $3.28 billion, up 42% year over year, fell short of the $3.34 billion consensus estimate.

NII increased 49% year over year to $2.28 billion, supported by the addition of Comerica, fixed-rate asset repricing and balance sheet management. Non-interest income rose 29% to $1.01 billion, while non-interest expenses climbed 62% to $2.05 billion, reflecting higher compensation, technology costs and merger-related charges. The net interest margin improved to 3.34% from 3.13% a year earlier.

Credit indicators were mixed. Provisions for credit losses declined 38% to $122 million, while net charge-offs fell to $139 million from $339 million. Non-performing loans and leases increased to $1.07 billion from $768 million. The common equity Tier 1 capital ratio declined to 10.02% from 10.57%.

For the fourth quarter, the bank expects NII to rise 2.5–3.5% sequentially and adjusted non-interest expenses to fall 2–3%.

Shares traded at $50.93, up 1.06% during the session. The stock opened at $50.35, reached a high of $51.47 and a low of $50.14.

Eos Energy Shares Fall 0.55% Despite 169% Revenue Growth in Q3 2026

Eos Energy Enterprises, Inc. (NASDAQ: EOSE) reported preliminary third-quarter 2026 revenue of $82 million to $83 million, representing year-over-year growth of 169% to 172%, according to its 19 October announcement. Despite the strong revenue growth, shares traded at $1.82, down 0.55% during the session. The stock opened at $2.02, reached an intraday high of $2.02 and a low of $1.81. The previous closing price was not provided in the supplied market data.

The company expects sequential revenue growth of 19% to 21%, while shipments increased approximately 23% quarter over quarter. Its GAAP gross margin is projected to range between negative 55% and negative 53%, improving by 16 to 18 percentage points from the second quarter. Eos said this would mark its eighth consecutive quarter of gross margin improvement.

Total cash, including restricted cash, stood at approximately $344 million on 30 September, down from $364 million at the end of June. Operating cash inflows reached approximately $114 million, primarily from customer deposits, project milestone receipts and tax credit collections. The company also received an $87 million advance under its US Department of Energy loan facility, while capital expenditure totalled approximately $35 million.

Eos reported a backlog of approximately $765 million, equivalent to 3.2 GWh, and received six purchase orders from six customers during the quarter. Its second manufacturing line contributed around 17% of total battery production.

For 2026, the company expects revenue in the lower half of its $300 million to $350 million guidance range. Full third-quarter results are scheduled for 5 November 2026.

GoPro Shares Rise 0.95% as Merger Proxy Filing Advances Starman Deal

GoPro Inc. (NASDAQ: GPRO) filed a preliminary proxy statement with the US Securities and Exchange Commission on 19 October 2026, marking another step towards its proposed merger with Starman Optical Inc. Despite the announcement, shares traded at $1.06, up 0.95% during the session. The stock opened at $1.12, reached an intraday high of $1.19 and a low of $1.06. The previous closing price was not provided in the supplied market data.

GoPro founder and Chief Executive Nicholas Woodman said the filing advances the process towards closing the transaction, while Starman Holding CEO Charles Tebele reaffirmed both companies’ commitment to completing the merger on previously announced terms. The announcement did not provide a revised completion date.

Separately, GoPro filed amendments to its 2025 annual report and quarterly reports for the periods ended 31 March and 30 June 2026 to restate certain financial statements. The revisions address accounting errors involving warrant valuations associated with debt agreements and the measurement of an embedded conversion derivative liability linked to convertible debentures issued in February 2026.

According to the company, the restatement involves non-cash accounting adjustments and does not affect previously reported revenue or operating cash flows for the periods concerned. However, the accounting errors constituted defaults or events of default under its credit facilities, convertible debentures and senior secured notes. GoPro said it had obtained waivers covering the relevant financing arrangements.

Further details are available in the company’s regulatory filings, including its Form 8-K filed on 16 October 2026.

Also Read: How to invest in US stocks

TriGemX Bio Deal Targets $600 Million Valuation as $160 Million PIPE Funds Migraine Drug

TriGemX Bio and TCGX Acquisition Corp. (Nasdaq: TCGX) have signed a definitive business combination agreement to take the biotechnology company public, with the combined entity expected to trade under the ticker TGEM. Announced on 19 October 2026, the transaction includes a $160 million private investment in public equity (PIPE) financing and approximately $246 million in total gross proceeds, assuming no shareholder redemptions and before transaction costs.

The proceeds comprise approximately $86 million from TCGX’s trust account and $160 million from investors, including Viking Global Investors, ADAR1 Capital Management and BVF Partners. PIPE shares are priced at $10 each, while the combined company is expected to have an equity value of approximately $600 million at closing.

TriGemX plans to use the funding to advance elismetrep, its investigational acute migraine treatment, through Phase 3 trials and support a potential New Drug Application submission. Funding will also support a separate study exploring migraine prevention and preparations for a possible US commercial launch.

TriGemX shareholders will roll over all their equity without receiving cash proceeds. Both boards have approved the agreement, with completion expected in the first quarter of 2027, subject to shareholder approvals and customary conditions. Elismetrep remains investigational, and commercialisation depends on clinical and regulatory progress.

Palantir Stock Gains 4.38% as Knox Systems Partnership Targets Faster Federal Software Deployment

Palantir Technologies (NASDAQ: PLTR) shares rose on Monday, 19 October 2026, after the company announced a partnership with Knox Systems to help commercial software providers deploy applications in secure US government and defence environments. The collaboration combines Palantir’s accredited infrastructure with Knox’s process for accelerating federal cloud authorisation, targeting customers operating under the Federal Risk and Authorisation Management Program (FedRAMP) and Impact Level 5 (IL5) security requirements.

At the latest reported market snapshot, Palantir shares traded at $194.14, up 4.38%. The stock opened at $187.00, reached an intraday high of $196.99 and a low of $186.16. The rebound followed a five-session losing streak that had left shares more than 10% below their record high, according to market coverage published on Monday.

The partnership is intended to help commercial software developers bring mission-critical applications to government and defence customers more quickly while meeting stringent security requirements. Knox said it supports more than 100 AI and enterprise software applications across federal environments and can secure FedRAMP authorisation in 90 days or less. Palantir said the collaboration would help address barriers that can delay the deployment of commercial technology in regulated government settings.

However, the companies did not disclose financial terms, expected revenue contributions or the number of additional software providers likely to use the combined offering. The announcement therefore establishes the partnership’s intended operational scope without quantifying its potential financial impact.

Palantir’s share recovery also coincided with a broader rebound in software stocks, including Datadog and Snowflake, while the software-focused iShares Expanded Tech-Software Sector ETF also advanced. Market attention is likely to remain on the company’s forthcoming quarterly results, scheduled for 2 November, when investors will receive an updated view of revenue growth and demand for its artificial intelligence-related offerings.

TTM Technologies Shares Trade at $97.44 as $650 Million Ophir Optics Acquisition Expands Capabilities

TTM Technologies (NASDAQ: TTMI) has agreed to acquire MKS Inc.’s Ophir Optics business for approximately $650 million in cash, expanding its infrared imaging and laser optics capabilities across defence, security and industrial markets. Announced on 19 October 2026, the transaction remains subject to regulatory approvals, governmental consents and other customary closing conditions.

TTM expects the acquisition to immediately increase its adjusted EBITDA margin and non-GAAP diluted earnings per share. The purchase price represents approximately 10.3 times Ophir Optics’ projected financial year 2027 adjusted EBITDA, excluding synergies. MKS separately valued the transaction at more than 18 times projected financial year 2026 adjusted EBITDA, reflecting different earnings periods.

The acquisition will be financed through available cash, anticipated future cash flows and borrowings under TTM’s existing revolving credit facility. It complements the company’s previously announced $400 million investment in Asian capital and capacity expansion. Ophir Optics’ technologies serve defence platforms across land, air, maritime and unmanned systems, alongside industrial applications.

At the latest reported market snapshot on 19 October, TTM shares traded at $97.44, after opening at $98.65 and reaching an intraday high of $100.46 and a low of $96.23. The previous closing price was unavailable.

The acquisition is expected to close in the second quarter of 2027. Ophir Instruments and its brand are excluded, with existing products, services and customer support remaining unaffected.

Data I/O Shares Fall 0.81% as Company Announces $13.25 Million Private Placement

Data I/O Corporation (NASDAQ: DAIO) has announced a private placement worth approximately $13.25 million through convertible subordinated debentures and common shares. Announced on 19 October 2026, the financing is expected to close within days, subject to customary conditions, providing additional capital for its semiconductor programming and security provisioning business.

At the latest reported market snapshot, Data I/O shares traded at $2.56, down 0.81%. The stock opened at $2.57, reached an intraday high of $3.05 and a low of $2.51. The previous closing price was not provided.

The financing includes $7.25 million in debentures automatically convertible into common stock at $2.68 per share, alongside $4 million convertible into non-voting preferred shares at $1,000 each. These preferred shares can subsequently convert into common stock at $2.68 per share. The five-year debentures carry 5% interest in the first year, rising by one percentage point annually thereafter.

The lead investor from the June 2026 placement has committed another $4 million. Following closing, Data I/O plans to seek shareholder approval within 120 days to issue common stock exceeding 19.9% of outstanding shares and file a Form S-1 registration statement within 30 days. Completion remains pending, and the securities are subject to applicable registration requirements or exemptions.

Also Read: US Stock Market Timings 

Dogwood Therapeutics Shares Fall 0.82% as CK Life Sciences Commits $5 Million

Dogwood Therapeutics (NASDAQ: DWTX) has secured a $5 million investment from a subsidiary of CK Life Sciences International, its largest shareholder, to advance its investigational pain treatment Halneuron. Announced on 19 October 2026, the private placement involves 4,098,360 common shares priced at $1.22 each, without warrants or derivative securities.

At the latest reported snapshot, Dogwood shares traded at $1.21, down 0.82%, after opening at $1.40 and reaching a high of $1.40 and a low of $1.20. The previous closing price was not provided.

The proceeds will fund Phase 3 preparations and extend the company’s operational runway through March 2027. Dogwood is also advancing its Phase 2b HAL-CINP trial, which is evaluating Halneuron against a placebo in 239 patients with moderate to severe chemotherapy-induced neuropathic pain. Topline results are expected in November 2026.

Conducted at approximately 25 US sites, the study evaluates Halneuron, a non-opioid sodium channel modulator that has received US Food and Drug Administration Fast Track designation for this indication.

The transaction is expected to close by 29 October 2026. While the funding supports clinical development, the upcoming trial results remain a key programme milestone.

Freight Technologies Shares Fall 9.70% as 1-for-10 Reverse Split Reshapes Capital Structure

Freight Technologies (NASDAQ: FRGT) shares fell 9.70% on Monday, 19 October 2026, as the company implemented a 1-for-10 reverse share split and restructured its preferred securities and warrants. At the latest reported snapshot, shares traded at $1.34, after opening at $2.01, reaching a high of $2.15 and a low of $1.29.

On 18 October, the company entered exchange agreements covering 1,666,837 Series A4 and 3.19 million Series C preferred shares. Holders received rights to a combined 6,435,332 ordinary shares on a post-split basis, without additional payment. The exchange terms imply prices of $1.87 per share for Series A4 and $1.00 for Series C, subject to a 9.99% beneficial ownership limit.

Freight Technologies also confirmed that all remaining ordinary share warrants issued under its 2023 convertible note financing had been exercised. The reverse split took effect on 19 October, with Nasdaq trading on a split-adjusted basis.

The company is shifting towards recurring software revenue through Fleet Rocket and Zayren, alongside its Sendengo arrangement. However, current software revenue and profitability remain undisclosed. The exchange rights could also create share dilution, while the reverse split alone does not increase underlying business value.

L3Harris Shares Fall 1.28% Despite $876 Million US Navy Jammer Contract Award

L3Harris Technologies (NYSE: LHX) has secured an $876.44 million contract modification from the US Navy to advance its Next Generation Jammer Low Band (NGJ-LB) programme into the engineering and manufacturing development phase. Announced on 19 October 2026, the undefinitised award supports accelerated delivery of electronic warfare capabilities designed to disrupt adversary radar and communications systems.

L3Harris shares traded at $245.32, down 1.28%, during the reported session. The stock opened at $245.16, reached an intraday high of $246.89 and a low of $242.95, compared with the previous close of $248.51. Available information does not establish that the contract announcement caused the decline.

The NGJ-LB system will combine advanced jamming capabilities with faster processing to help naval aviators counter lower-frequency threats. Its modular, open-system architecture is designed to simplify maintenance and accommodate future upgrades while supporting interoperability with allied forces.

Under the award, L3Harris will provide equipment, demonstration test pods, cybersecurity development, testing, evaluation, software and logistics support to the US Naval Air Systems Command. The programme builds on its existing electronic warfare work, including the AN/ALQ-99 Tactical Jamming System, and supports defence-related employment in Utah. However, the announcement did not specify the contract’s expected revenue recognition schedule or profit contribution.

Today’s trading session reflected a mix of corporate developments, including acquisitions, clinical trial progress, defence contracts, funding agreements and strategic partnerships. While share-price movements varied across companies, the announcements highlighted developments in their respective business operations, financing plans and growth strategies. Their longer-term significance will depend on execution, regulatory outcomes, commercial progress and the financial results reported in subsequent periods.